Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure
Endoscopy · 01.11.2023 · 55 (11) · 1028-1034
DOI: 10.1055/a-2117-6274 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Endoscopy, erschienen am 01.11.2023. Verfasst von Maryam AlKhatry und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Insulin Resistance. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: UAE Ministry of Health.
Abstract (Originalsprache)
Background
The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity.
Methods
Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety.
Results
42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events.
Conclusion
POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
- Gastroenterology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.
ORCID-Profile: Donna Maria Abboud, Vitor O Brunaldi, Eric J Vargas, Andrew C Storm
Förderung
- UAE Ministry of Health
Zitieren
APA
AlKhatry, M., Rapaka, B., Maselli, D. B., Abboud, D. M., Brunaldi, V. O., Mahmoud, T., Ghazi, R., Abdul Razzak, F., Gala, K., Joudah, I., Housen, F., Al Qadi, S., Vargas, E. J., Storm, A. C., & Abu Dayyeh, B. K. (2023). Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure. Endoscopy, 55(11), 1028-1034. https://doi.org/10.1055/a-2117-6274
Vancouver
AlKhatry M, Rapaka B, Maselli DB, Abboud DM, Brunaldi VO, Mahmoud T, et al. Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure. Endoscopy. 2023;55(11):1028-1034. doi:10.1055/a-2117-6274
BibTeX
@article{AlKhatry2023,
author = {AlKhatry, Maryam and Rapaka, Babusai and Maselli, Daniel B and Abboud, Donna Maria and Brunaldi, Vitor O and Mahmoud, Tala and Ghazi, Rabih and Abdul Razzak, Farah and Gala, Khushboo and Joudah, Imad and Housen, Fedaa and Al Qadi, Sana and Vargas, Eric J and Storm, Andrew C and Abu Dayyeh, Barham K},
title = {Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure},
journal = {Endoscopy},
year = {2023},
volume = {55},
number = {11},
pages = {1028--1034},
doi = {10.1055/a-2117-6274}
}
EUVIMED